Previous close | 1.3000 |
Open | 1.3000 |
Bid | 1.0000 |
Ask | 1.5000 |
Strike | 135.00 |
Expiry date | 2025-01-17 |
Day's range | 1.3000 - 1.3000 |
Contract range | N/A |
Volume | |
Open interest | 92 |
Exact Sciences' (EXAS) latest study research result shows commitment to innovation and strategies that expand access to effective cancer screening and diagnostic tools for patients.
MADISON, Wis., May 28, 2024--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conferences and invited investors to participate by webcast.
We recently compiled a list of the 7 Best Mid-Cap Healthcare Stocks To Buy Now and in this article we discuss why hedge funds have sizable positions in Exact Sciences Corporation (NASDAQ:EXAS). Challenges in the Health Sector The healthcare industry is considered to be a fairly defensive sector due to its need. According to a World […]